Literature DB >> 17384224

Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7.

Ankur Kapur1, Dow P Hurst, Daniel Fleischer, Rob Whitnell, Ganesh A Thakur, Alexandros Makriyannis, Patricia H Reggio, Mary E Abood.   

Abstract

Ligands of structurally diverse natures are able to bind at the CB(1) cannabinoid receptor, suggesting the existence of multiple binding sites on the receptor. Modeling studies have implicated Ser2.60(173) and Ser7.39(383) as possible interaction site(s) for CB(1) agonists. To test the importance of these residues for receptor recognition, recombinant human CB(1) receptors, stably expressed in human embryonic kidney 293 cells, were used to investigate the consequences of mutating Ser2.60 (to S2.60A) or Ser7.39 (to S7.39A) in radioligand binding and guanosine 5'-3-O-(thio)triphosphate functional assays. The S7.39A mutant resulted in a total ablation of [(3)H](-)-3-[2-hydroxyl-4-(1,1-dimethylheptyl)phenyl]-4-[3-hydroxylpropyl] cyclohexan-1-ol (CP55,940) high-affinity binding. However, [(3)H](R)-(+)-[2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]-pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl](1-naphthalenyl)methanone (WIN55,212-2) binding properties at S7.39A were comparable with those of the wild-type (WT) receptor. The binding affinity of (-)-11beta-hydroxy-3-(1',1'-dimethylheptyl)hexahydrocannabinol (AM4056) and (-)-11-hydroxydimethylheptyl-Delta(8)-tetrahydrocannabinol (HU210) were drastically reduced (50- to 100-fold) at the S7.39A mutant. Likewise, the EC(50) for HU210 and AM4056-mediated activation of the S7.39A receptor was increased by >200-fold. In contrast, the binding affinity and potency of WIN55,212-2, CP55,940, HU210, and AM4056 were unaltered at the S2.60A mutant compared with WT human CB(1) receptors. These results clearly suggest that Ser7.39, but not Ser2.60, plays a crucial role in mediating ligand specific interactions for CP55,940, HU210, and AM4056 at the human CB(1) receptor. Our modeling studies predict that Ser7.39 in a g-chi1 conformation may induce a helix bend in TMH7 that provides docking space for CP55,940 binding; the S7.39A mutation may alter this binding space, precluding CP55,940 binding.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17384224     DOI: 10.1124/mol.107.034645

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  42 in total

1.  Ligand Binding Sensitivity of the Extracellular Loop Two of the Cannabinoid Receptor 1.

Authors:  Alexander C Bertalovitz; Kwang H Ahn; Debra A Kendall
Journal:  Drug Dev Res       Date:  2010-11-01       Impact factor: 4.360

2.  Chromenopyrazoles: non-psychoactive and selective CB₁ cannabinoid agonists with peripheral antinociceptive properties.

Authors:  Jose Cumella; Laura Hernández-Folgado; Rocio Girón; Eva Sánchez; Paula Morales; Dow P Hurst; Maria Gómez-Cañas; Maria Gómez-Ruiz; Diana C G A Pinto; Pilar Goya; Patricia H Reggio; María Isabel Martin; Javier Fernández-Ruiz; Artur M S Silva; Nadine Jagerovic
Journal:  ChemMedChem       Date:  2012-02-02       Impact factor: 3.466

3.  Identification of essential cannabinoid-binding domains: structural insights into early dynamic events in receptor activation.

Authors:  Joong-Youn Shim; Alexander C Bertalovitz; Debra A Kendall
Journal:  J Biol Chem       Date:  2011-07-27       Impact factor: 5.157

4.  Chemogenomics knowledgebase and systems pharmacology for hallucinogen target identification-Salvinorin A as a case study.

Authors:  Xiaomeng Xu; Shifan Ma; Zhiwei Feng; Guanxing Hu; Lirong Wang; Xiang-Qun Xie
Journal:  J Mol Graph Model       Date:  2016-08-08       Impact factor: 2.518

5.  Molecular-interaction and signaling profiles of AM3677, a novel covalent agonist selective for the cannabinoid 1 receptor.

Authors:  David R Janero; Suma Yaddanapudi; Nikolai Zvonok; Kumar V Subramanian; Vidyanand G Shukla; Edward Stahl; Lei Zhou; Dow Hurst; James Wager-Miller; Laura M Bohn; Patricia H Reggio; Ken Mackie; Alexandros Makriyannis
Journal:  ACS Chem Neurosci       Date:  2015-05-29       Impact factor: 4.418

6.  Synthesis and pharmacology of 1-methoxy analogs of CP-47,497.

Authors:  John W Huffman; Seon A Hepburn; Patricia H Reggio; Dow P Hurst; Jenny L Wiley; Billy R Martin
Journal:  Bioorg Med Chem       Date:  2010-06-22       Impact factor: 3.641

7.  Novel insights into CB1 cannabinoid receptor signaling: a key interaction identified between the extracellular-3 loop and transmembrane helix 2.

Authors:  Jahan Marcu; Derek M Shore; Ankur Kapur; Megan Trznadel; Alexandros Makriyannis; Patricia H Reggio; Mary E Abood
Journal:  J Pharmacol Exp Ther       Date:  2013-02-20       Impact factor: 4.030

Review 8.  Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.

Authors:  V Kiran Vemuri; David R Janero; Alexandros Makriyannis
Journal:  Physiol Behav       Date:  2007-11-21

Review 9.  Endogenous lipid activated G protein-coupled receptors: emerging structural features from crystallography and molecular dynamics simulations.

Authors:  Dow P Hurst; Marianne Schmeisser; Patricia H Reggio
Journal:  Chem Phys Lipids       Date:  2013-02-26       Impact factor: 3.329

10.  PKCepsilon regulates behavioral sensitivity, binding and tolerance to the CB1 receptor agonist WIN55,212-2.

Authors:  Melisa J Wallace; Philip M Newton; Thomas McMahon; Jacklyn Connolly; Anne Huibers; Jennifer Whistler; Robert O Messing
Journal:  Neuropsychopharmacology       Date:  2009-01-21       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.